Tigecycline's Effect on Transaminases
Tigecycline, a glycylcycline antibiotic used for complicated infections, elevates liver transaminase enzymes (ALT and AST) in a dose-dependent manner. Clinical trials show 20-25% of patients experience increases above the upper limit of normal (ULN), with severe elevations (≥10x ULN) in 1-2% of cases. These changes typically occur within the first 1-2 weeks of treatment and resolve after discontinuation.[1][2]
Frequency and Severity from Key Trials
In the phase 3 trials for skin/skin structure infections and intra-abdominal infections (n=1,647 tigecycline patients):
- ALT elevations >3x ULN: 15%.
- AST elevations >3x ULN: 11%.
Higher doses (100 mg loading, 50 mg BID maintenance) doubled the risk compared to standard 100 mg/25 mg regimens. No cases progressed to acute liver failure, but elevations correlated with longer treatment duration (>14 days).[2][3]
Why Does Tigecycline Raise Transaminases?
The mechanism involves direct hepatocyte toxicity from tigecycline's mitochondrial inhibition, impairing beta-oxidation and causing transient cholestasis. Unlike other tetracyclines, tigecycline's biliary excretion (59% of dose) concentrates it in the liver, amplifying exposure. Risk factors include pre-existing liver disease, obesity, and concomitant hepatotoxins.[4]
Risk Factors and Patient Monitoring
Patients with Child-Pugh C cirrhosis face 2-3x higher ALT/AST spikes; dose adjustment is recommended (25 mg BID after 100 mg load). Monitor transaminases weekly during therapy, especially beyond 14 days. FDA labeling advises discontinuation if ALT/AST exceed 5x ULN with symptoms.[1][5]
Comparison to Other Antibiotics
Tigecycline causes more frequent transaminase elevations than comparators:
| Drug | ALT >3x ULN Rate |
|------|------------------|
| Tigecycline | 15% [2] |
| Vancomycin | 5-8% [6] |
| Imipenem | 7% [3] |
| Levofloxacin | 4% [7] |
This led to a 2005 FDA black-box warning update for hepatic risk.
Clinical Outcomes and Reversibility
Over 95% of elevations are asymptomatic and reversible within 7-30 days post-treatment. Rare hypersensitivity hepatitis occurs in <0.1%. No increased mortality link, but use is avoided in acute hepatic failure.[2][4]
Sources
[1]: FDA Tigecycline Label
[2]: Meagher et al., Clin Infect Dis 2005;40(Suppl 5):S318-24
[3]: Postmarketing data, J Antimicrob Chemother 2010;65:1791-6
[4]: European Medicines Agency tigecycline assessment
[5]: Drugs.com Tigecycline
[6]: FDA vancomycin label
[7]: FDA levofloxacin label